Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_2
2
67%
Ph phase_4
1
33%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Not yet recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (66.7%)
Phase 41 (33.3%)

Trials by Status

completed133%
not_yet_recruiting267%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_2

A Trial of Baricitinib in Patients With Cardiac Sarcoidosis

NCT06868381
not_yet_recruitingphase_4

JAK Inhibitor Dose TAPering Strategy Study

NCT06687551
completedphase_2

Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

NCT05188521

Clinical Trials (3)

Showing 3 of 3 trials
NCT06868381Phase 2

A Trial of Baricitinib in Patients With Cardiac Sarcoidosis

Not Yet Recruiting
NCT06687551Phase 4

JAK Inhibitor Dose TAPering Strategy Study

Not Yet Recruiting
NCT05188521Phase 2

Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3